{
}
Novo Nordisk's shares have dropped over 20% this year, primarily due to disappointing results for its weight loss drug CagriSema and concerns about Wegovy's market performance against Eli Lilly's Zepbound. Despite this, UBS maintains a "buy" rating with a target price of 750 DKK, suggesting a potential 56% upside. Wall Street remains divided, with half of analysts recommending a buy and the other half advising to hold, but no sell ratings are present.
Hims & Hers Health stock fell 7.4% after Bank of America raised its price target by only $1 to $22, which is $10 below its current value. The bank reiterated its "underperform" rating, citing concerns over slowing growth due to the FDA's actions affecting GLP-1 product sales. With the stock trading at 65 times trailing earnings, analysts question its investment worthiness at this price.
This week marked a significant surge in mergers and acquisitions across Asia's tech landscape, with 86 deals totaling over US$680 million. Notable transactions include Zolve's US$251 million funding in India and Otorio's US$120 million acquisition by Armis in Israel. The momentum suggests a robust start to March, potentially signaling a revitalization in the region's investment climate.
This week saw a surge in mergers and acquisitions across Asia's tech landscape, with 86 deals totaling over US$680 million. Notable transactions include Zolve's US$251 million funding in India and Otorio's US$120 million acquisition by Armis in Israel. The momentum suggests a robust start to March as the region's startup ecosystem continues to evolve.
Insilico Medicine, an AI-driven drug discovery company, has raised $110 million in its Series E funding round, achieving a valuation of over $1 billion. The funding, led by Value Partners Group, will enhance its AI platform and support the clinical development of Rentosertib for idiopathic pulmonary fibrosis, which has completed Phase IIa trials.With a pipeline of 30 drug assets, including 10 approved by the US FDA for investigational use, Insilico also licenses its assets to firms like Fosun Pharma and Exelixis, securing contracts worth approximately $3.5 billion. The company is advancing its proprietary AI system, “pharma.ai,” and developing humanoid robots to automate lab processes.
Insilico Medicine, an AI-driven drug discovery company, has raised $110 million in its Series E funding round, achieving a valuation of over $1 billion. The investment, led by Value Partners Group, will enhance its AI platform and support the clinical development of Rentosertib for idiopathic pulmonary fibrosis, which has completed Phase IIa trials.With a pipeline of 30 drug assets, including 10 approved by the US FDA for investigational use, Insilico also licenses its assets to firms like Fosun Pharma and Exelixis, securing contracts worth approximately $3.5 billion. The company is advancing its proprietary AI system, “pharma.ai,” and developing humanoid robots to automate lab processes.
Trading activity is subdued ahead of the Christmas holidays, with many market participants taking a break. The Dow is up 13% this year, while the Nasdaq 100 has nearly doubled that gain, despite Walmart shares dropping over 3% due to a lawsuit. Oil prices fell as the dollar strengthened, impacting crude costs.
U.S. stocks showed mixed results as the Dow dipped 0.2%, while the S&P 500 and Nasdaq rose 0.3% and 0.7%, respectively, amid hopes for a Santa Claus rally. Eli Lilly's shares climbed after the approval of its weight-loss drug for sleep apnea, while Treasury yields hit a new high at 4.58%. Economic data revealed a drop in consumer confidence and disappointing new home sales, with the stock market closing early on Tuesday and remaining shut on Wednesday.
Sandoz Group AG is set to launch a generic version of Ozempic in Canada by 2026, aiming to compete with Novo Nordisk A/S. The Swiss company anticipates strong demand for GLP-1 weight-loss drugs, particularly due to the high costs of branded options, despite advancements from competitors like Eli Lilly & Co.
Eli Lilly is recommended as a buy, despite its fluctuating stock performance. Coinbase is highlighted as a winner, while IES is noted as a strong infrastructure investment. Marvell Technology is favored, and Apple is advised to be held long-term, with a suggestion to buy on dips. Conversely, Cameco is considered overpriced, and Semtech is viewed as a traditional semiconductor company, with a preference for Texas Instruments.
Eli Lilly
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs predicts over 50 percent recovery for novo nordisk shares
19:30 28.03.2025
hims and hers stock declines after bank of america raises price target
Euro
United States Dollar
Hims & Hers Health, Inc.
Novo Nordisk A/S
Bank of America Corporation
Eli Lilly and Co
USA
Eli Lilly
Show more
16:40 18.03.2025
Asia's tech sector sees record M&A activity and significant funding deals
Australian Dollar
Chinese Yuan
Hong Kong Dollar
United States Dollar
METISA ON
Sola Security Ltd.
Vuno Inc.
SNB SONDERSATZ
Insilico Medicine
JPN
NGA
IND
IDN
KOR
SGP
ISR
THA
CHN
Mike Moritz
Eli Lilly
Fred Armisen
Rakesh Perfios
Show more
10:30 15.03.2025
asia's tech sector sees surge in mergers and acquisitions this week
Chinese Yuan
Hong Kong Dollar
United States Dollar
Australian Dollar
Insilico Medicine
Sola Security Ltd.
JPN
KOR
IDN
HKG
IND
SGP
THA
ISR
NGA
CHN
Mike Moritz
Fred Armisen
Rakesh Perfios
Eli Lilly
Show more
10:30 15.03.2025
Insilico Medicine secures 110 million dollars in series E funding round
04:50 13.03.2025
Insilico Medicine secures 110 million dollars in series E funding round
United States Dollar
FOSUN PHARM
Eli Lilly & Co
Exelixis, Inc.
Value Partners Group Ltd
Orbimed Advisors LLC
USA
CHN
Eli Lilly
Show more
04:50 13.03.2025
trading activity slows ahead of christmas as markets prepare for new year
Euro
United States Dollar
Japanese Yen
Swiss Franc
Walmart Inc.
Relief Therapeutics Holding SA
Micron Technology, Inc.
Eli Lilly and Company
Novartis AG
Tether USDt CNY
WISeKey Internat.Holding Ltd. N
USD/AMD
Broadcom Inc.
Qualcomm Inc
RumbleOn, Inc.
Apple Inc.
Arm Holdings plc
Hoffmann-La Roche AG
Nestlé S.A.
Eli Lilly
Show more
07:03 27.12.2024
mixed market performance as chip stocks boost nasdaq and eli lilly rises
United States Dollar
Apple Inc.
Amazon.com, Inc.
Eli Lilly and Company
Microsoft Corp
MicroStrategy Inc
Tesla, Inc.
NVIDIA Corporation
Alphabet Inc.
USA
Eli Lilly
Joe Biden
Show more
15:02 23.12.2024
sandoz plans generic ozempic launch in canada by 2026
13:12 11.12.2024
Cramer endorses Eli Lilly and Coinbase while advising caution on Cameco
Coinbase Global, Inc.
Marvell Technology
Cameco Corporation
Apple Inc.
Semtech Corporation
Eli Lilly and Company
Apple
Marvell Technology
Eli Lilly
Texas Instruments
Jim Cramer
Show more
01:16 19.11.2024
Trending
Subcategory
Corporate News
Startups & Entrepreneurship
Economic Indicators
Global Trade Developments
Market Analysis and Predictions
Countries:
Companies:
Currencies:
People: